Fellowship · Galveston, TX
Sponsored by University of Texas Medical Branch Hospitals
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Lancet (London, England) · 2024 · 686 citations · Ryan Sullivan
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
The New England journal of medicine · 2021 · 741 citations · Ryan Sullivan
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 226 citations · Subodh Lele
Cutaneous melanoma.
Nature reviews. Disease primers · 2025 · 91 citations · Ryan Sullivan
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Nature medicine · 2025 · 94 citations · Ryan Sullivan
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer.
Cell · 2021 · 479 citations · Ryan Sullivan
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 259 citations · Subodh Lele
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
The New England journal of medicine · 2023 · 246 citations · Ryan Sullivan